

## PTO-1449

SERIAL NO.  
09/800.770

FILING DATE  
March 6, 2001

GROUP  
~~UNKNOWN~~ 1639

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

TDW	C22	Evans, T.C. et al., "Protein <i>trans</i> -Splicing and Cyclization by a Naturally Split Intein from the <i>dnaE</i> Gene of <i>Synechocystis</i> Species PCC6803," <i>J Biol Chem</i> 275(13):9091-9094 (2000)

**EXAMINER**

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

no persons are required to see

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

*Complete if Known*

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

<b>Application Number</b>	09/800,770
<b>Filing Date</b>	March 6, 2001
<b>First Named Inventor</b>	KINSELLA, Todd
Group Art Unit	1639
Examiner Name	T. Wilson
Attorney Docket Number	A-68614-1/RMS/AXG

Sheet	1	of	3
-------	---	----	---

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]


Examiner Signature	T. Alexander	Date Considered	5/16/03
-----------------------	--------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	09/800,770
				<b>Filing Date</b>	March 6, 2001
				<b>First Named Inventor</b>	KINSELLA, Todd
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	T. Wessendorf
<b>Sheet</b>	2	of	3	<b>Attorney Docket Number</b>	A-68614-1/RMS/AXG

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
TW	C1	BRENNAND, D.M. et al. "Identification of a cyclic peptide inhibitor of platelet-derived growth factor-BB receptor-binding and mitogen-induced DNA synthesis in human fibroblasts." <i>FEBS Lett.</i> 1997 Aug 11;413(1):70-4.		
	C2	CAMARERO et al., "Chemical Synthesis of a Circular Protein Domain: Evidence for Folding-Assis," <i>Angew. Chem.</i> 37(3):347-349 (1998)		
	C3	CAMARERO and MUIR, "Biosynthesis of a Head-to-Tail Cyclized Protein with Improved Biological Activity," <i>J Am Chem Soc.</i> 1999; 121(23); 5597-5598.		
	C4	CAMARERO and MUIR, "Chemoselective backbone cyclization of unprotected peptides," <i>Chem Commun</i> 1997(15):1369-1370 (1997)		
	C5	ERIKSSON, J.E. et al. "Rapid microfilament reorganization induced in isolated rat hepatocytes by microcystin-LR, a cyclic peptide toxin." <i>Exp Cell Res.</i> 1989 Nov;185(1):86-100.		
	C6	EVANS, T.C. Jr, et al., "Semisynthesis of cytotoxic proteins using a modified protein splicing element." <i>Protein Sci.</i> 1998 Nov;7(11):2256-64.		
	C7	EVANS, T.C. Jr, et al., "The cyclization and polymerization of bacterially expressed proteins using modified self-splicing inteins." <i>J Biol Chem.</i> 1999 Jun 25;274(26):18359-63.		
	C8	FRIEDLER, A., et al., "Backbone cyclic peptide, which mimics the nuclear localization signal of human immunodeficiency virus type 1 matrix protein, inhibits nuclear import and virus production in nondividing cells." <i>Biochemistry.</i> 1998 Apr 21;37(16):5616-22.		
	C9	GOLDENBERG, D.P. and CREIGHTON, T.E. "Circular and circularly permuted forms of bovine pancreatic trypsin inhibitor." <i>J Mol Biol.</i> 1983 Apr 5;165(2):407-13.		
	C10	HRUBY, V.J., et al., "Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations." <i>Biochem J.</i> 1990 Jun 1;268(2):249-62.		
	C11	HRUBY, V.J. "Conformational restrictions of biologically active peptides via amino acid side chain groups." <i>Life Sci.</i> 1982 Jul 19;31(3):189-99.		
	C12	IWAI, H. and PLUCKTHUN, A. "Circular beta-lactamase: stability enhancement by cyclizing the backbone." <i>FEBS Lett.</i> 1999 Oct 8;459(2):166-72.		
	C13	JACKSON, D.Y. et al., "Enzymatic Cyclization of Linear Peptide Esters Using Subtiligase," <i>J Am Chem Soc</i> 117(2):819-820 (1995)		
	C14	JOIS, S.D. et al., "A Ca <sup>2+</sup> binding cyclic peptide derived from the alpha-subunit of LFA-1: inhibitor of ICAM-1/LFA-1-mediated T-cell adhesion." <i>J Pept Res.</i> 1999 Jan;53(1):18-29.		
	C15	KIMURA, K., et al. "Propeptin, a new inhibitor of prolyl endopeptidase produced by Microbispora. I. Fermentation, isolation and biological properties." <i>J Antibiot (Tokyo).</i> 1997 May;50(5):373-8.		
	C16	KOIVUNEN, E., et al., "Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins." <i>Biotechnology (N Y).</i> 1995 Mar;13(3):265-70.		
✓	C17	SCOTT, C.P., et al. "Production of cyclic peptides and proteins in vivo." <i>Proc Natl Acad Sci USA.</i> 1999 Nov 23;96(24):13638-43.		


<b>Examiner Signature</b>	T. Wessendorf	<b>Date Considered</b>	5/16/03
---------------------------	---------------	------------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/800,770
				Filing Date	March 6, 2001
				First Named Inventor	KINSELLA, Todd
				Group Art Unit	1629
Examiner Name	T. Wernsdorff				
Sheet	3	of	3	Attorney Docket Number	A-68614-1/RMS/AXG

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
TW	C18	SOUTHWORTH, M.W. et al., "Control of protein splicing by intein fragment reassembly." <i>EMBO J.</i> 1998 Feb 16;17(4):918-26.		
	C19	TAM, J.P. and LU, Y.A. "A biomimetic strategy in the synthesis and fragmentation of cyclic protein." <i>Protein Sci.</i> 1998 Jul;7(7):1583-92.		
	C20	WOOD, D.W., et al. "A genetic system yields self-cleaving inteins for bioseparations." <i>Nat Biotechnol.</i> 1999 Sep;17(9):889-92.		
	C21	ZHANG, L. and TAM, J.P., "Synthesis and Application of Unprotected Cyclic Peptides as Building Blocks," <i>J Am Chem Soc</i> 119(10):2363-2370 (1997)		

Examiner Signature	T. Wernsdorff	Date Considered	5/16/03
--------------------	---------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.